Sunshine Short Term Debt from 2010 to 2025

SBFM Stock  USD 2.16  0.04  1.89%   
Sunshine Biopharma Short Term Debt yearly trend continues to be very stable with very little volatility. Short Term Debt is likely to drop to about 129.6 K. During the period from 2010 to 2025, Sunshine Biopharma Short Term Debt quarterly data regression pattern had sample variance of 935.6 B and median of  480,124. View All Fundamentals
 
Short Term Debt  
First Reported
2008-03-31
Previous Quarter
114.5 K
Current Value
116.3 K
Quarterly Volatility
589.6 K
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Sunshine Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sunshine Biopharma's main balance sheet or income statement drivers, such as Interest Expense of 148.9 K, Other Operating Expenses of 34.9 M or Total Operating Expenses of 15.8 M, as well as many indicators such as Price To Sales Ratio of 0.3, Dividend Yield of 0.0 or PTB Ratio of 0.34. Sunshine financial statements analysis is a perfect complement when working with Sunshine Biopharma Valuation or Volatility modules.
  
Check out the analysis of Sunshine Biopharma Correlation against competitors.
To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.

Latest Sunshine Biopharma's Short Term Debt Growth Pattern

Below is the plot of the Short Term Debt of Sunshine Biopharma over the last few years. It is Sunshine Biopharma's Short Term Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sunshine Biopharma's overall financial position and show how it may be relating to other accounts over time.
Short Term Debt10 Years Trend
Slightly volatile
   Short Term Debt   
       Timeline  

Sunshine Short Term Debt Regression Statistics

Arithmetic Mean694,814
Geometric Mean263,286
Coefficient Of Variation139.21
Mean Deviation628,625
Median480,124
Standard Deviation967,273
Sample Variance935.6B
Range3.7M
R-Value0.34
Mean Square Error884.5B
R-Squared0.12
Significance0.19
Slope69,683
Total Sum of Squares14T

Sunshine Short Term Debt History

2025129.6 K
2024136.5 K
2023118.7 K
20223.8 M
20211.9 M
2020964.1 K
2019715.6 K

About Sunshine Biopharma Financial Statements

Sunshine Biopharma investors utilize fundamental indicators, such as Short Term Debt, to predict how Sunshine Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Short Term Debt136.5 K129.6 K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Sunshine Biopharma is a strong investment it is important to analyze Sunshine Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sunshine Biopharma's future performance. For an informed investment choice regarding Sunshine Stock, refer to the following important reports:
Check out the analysis of Sunshine Biopharma Correlation against competitors.
To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.
You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sunshine Biopharma. If investors know Sunshine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sunshine Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(127.90)
Revenue Per Share
197.42
Quarterly Revenue Growth
0.416
Return On Assets
(0.11)
Return On Equity
(0.18)
The market value of Sunshine Biopharma is measured differently than its book value, which is the value of Sunshine that is recorded on the company's balance sheet. Investors also form their own opinion of Sunshine Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sunshine Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sunshine Biopharma's market value can be influenced by many factors that don't directly affect Sunshine Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sunshine Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sunshine Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sunshine Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.